Loading...
Market
Where will HS-10535 primarily launch by end of 2026?
2
Resolution / Starting Odds
China • 25%
Other • 25%
United States • 25%
Europe • 25%
Merck's official press releases and market reports
Story
Merck Licenses Oral GLP-1 Drug from Hansoh Pharma for Potential Cardiometabolic Benefits in $2 Billion Deal
Dec 18, 2024, 12:15 PM
Merck & Co. Inc. has entered into an exclusive global license agreement with Hansoh Pharma, a Chinese biopharmaceutical company, for the development, manufacture, and commercialization of HS-10535, an investigational preclinical oral small molecule GLP-1 receptor agonist. The agreement includes an upfront payment of $112 million to Hansoh Pharma, with the potential for up to $1.9 billion in milestone payments and royalties on sales. Merck aims to leverage this deal to enhance its pipeline in cardiometabolic diseases, focusing on the potential of HS-10535 to provide cardiometabolic benefits beyond weight reduction. The transaction reflects Merck's strategy to augment its offerings in the growing obesity drug market, which is expected to reach over $100 billion annually by the early 2030s.
View original story
Similar markets
Military satellite launch • 25%
Commercial satellite launch • 25%
Scientific mission • 25%
Other • 25%
Geostationary orbit • 25%
Low Earth orbit • 25%
Polar orbit • 25%
Other • 25%
Japan • 50%
USA • 25%
EU • 25%
Spaceport Kii • 25%
Tanegashima Space Center • 25%
Uchinoura Space Center • 25%
Other • 25%
Less than 3 • 33%
3 to 5 • 33%
More than 5 • 33%
Earth Observation Satellite • 33%
Communication Satellite • 33%
Scientific Research Payload • 33%
SpaceX • 25%
Blue Origin • 25%
United Launch Alliance • 25%
Other • 25%
Moon • 25%
Mars • 25%
Geostationary Orbit • 25%
Other • 25%
Mission Success • 25%
Partial Success • 25%
Mission Failure • 25%
Mission Postponed • 25%
United Kingdom • 25%
France • 25%
Japan • 25%
Other • 25%
SpaceX • 25%
Blue Origin • 25%
Arianespace • 25%
Other • 25%